Shenzhen Hepalink Pharmaceutical Group (OTCMKTS:SHEZF) Cut to Sell at The Goldman Sachs Group

The Goldman Sachs Group lowered shares of Shenzhen Hepalink Pharmaceutical Group (OTCMKTS:SHEZF – Free Report) from a neutral rating to a sell rating in a research report sent to investors on Thursday morning, FlyOnTheWall reports. Shenzhen Hepalink Pharmaceutical Group Stock Performance SHEZF opened at $0.72 on Thursday. Shenzhen Hepalink Pharmaceutical Group has a twelve month […]

Related Keywords

United States ,Hong Kong ,China , ,Manufacturing Organization ,Shenzhen Hepalink Pharmaceutical Group Co Ltd ,Goldman Sachs Group ,Shenzhen Hepalink Pharmaceutical Group Company Profile ,Contract Development ,Shenzhen Hepalink Pharmaceutical Group ,Shenzhen Hepalink Pharmaceutical Group Stock Performance ,Free Report ,Get Free Report ,Mainland China ,Active Pharmaceutical Ingredients ,Shenzhen Hepalink Pharmaceutical Group Daily ,Otcmkts Shezf ,Shezf ,Medical ,Downgrade ,The Goldman Sachs Group Inc ,